Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03570749 · OUTCOME

Percentage of Participants Achieving SALT ≤ 20 - Phase 3 Open-Label Addendum

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata · Source last updated 2026-04-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
Week 52

What was measured

The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes.

Analysis population: All randomized phase 3 open-label addendum participants who had evaluable data for this outcome measure.

Groups in this outcome

4 mg Baricitinib Phase 3 Open-Label Addendum

Participants who received one 4 mg Baricitinib tablet administered orally QD.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
4 mg Baricitinib Phase 3 Open-Label Addendum11

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
4 mg Baricitinib Phase 3 Open-Label Addendum18.2Not reported5.147.7Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        5.1
        upper Limit
        47.7
        value
        18.2
denoms
  1. counts
    1. group Id
      OG000
      value
      11
    units
    Participants
description
The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants who received one 4 mg Baricitinib tablet administered orally QD.
    id
    OG000
    title
    4 mg Baricitinib Phase 3 Open-Label Addendum
param Type
NUMBER
population Description
All randomized phase 3 open-label addendum participants who had evaluable data for this outcome measure.
reporting Status
POSTED
time Frame
Week 52
title
Percentage of Participants Achieving SALT ≤ 20 - Phase 3 Open-Label Addendum
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice